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ABSTRACT;  
Symptomatic and functional recovery are important patient-reported outcome measures (PROMs) in 
community-acquired pneumonia (CAP) that are increasingly used as trial endpoints. This systematic 
review summarises the literature on PROMs in CAP. 
Comprehensive searches in accordance with the Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis (PRISMA) statement were conducted to March 2017. Eligible studies included 
adults discharged from hospital following confirmed CAP and reporting PROMs. 
Fifteen studies (n=5644 patients) were included; most of moderate quality. Studies used a wide 
range of PROMs and assessment tools. At 4-6 weeks’ post-discharge, the commonest symptom 
reported was fatigue (45% to 72.6% of patients, 3 studies), followed by cough (35.3% to 69.7%) and 
dyspnoea (34.2% to 67.1%), corresponding values from studies restricted by age <65 years (2 
studies) were lower; fatigue 12.1% to 25.7%, cough 19.9% to 31.9%, dyspnoea 16.8% to 27.5%. 
Functional impairment 4 weeks post-discharge was reported in 18% to 51% of patients (2 studies) 
while median time to return to normal activities was between 15 to 28 days (3 studies).  
Substantial morbidity is reported by patients up to 6 weeks post-discharge. There is weak 
methodological consistency across existing studies.  A core set of PROMs for use in future studies is 
suggested.  
 
  
PROMs in CAP recovery; a systematic review. 
Version 1.0 (10.12.18) 
Page 3 of 30 
 
INTRODUCTION 
Community-acquired pneumonia (CAP) affects approximately 1% of the UK adult population each 
year, accounting for over 100,000 hospital admissions.1 The average length of stay is 6 days and 
estimated direct healthcare costs are £441 million.2,3 Most patients survive their inpatient admission 
and are discharged to recuperate.4,5 In clinical practice, a patient is deemed to have recovered from 
CAP based on the clinical assessment of a physician, often in association with radiological 
improvement. In one study 78% of patients were deemed clinically cured at 4 weeks following 
discharge from hospital,6 while corresponding rates of radiological resolution vary between 53% and 
67%6-8  
However, there is discordance between physician rated clinical cure and radiographic resolution 
versus patient-reported symptoms and functional impairment.6 Patient-reported outcome measures 
(PROMs) are increasingly recognised as providing a more robust indication of patient experienced 
morbidity during recovery.9 As a reflection of this, recent US Food and Drug Administration (FDA) 
guidance on drug development in CAP recommends incorporation of PROMs as trial endpoints.10 The 
aim of this study was to systematically gather and summarise the available literature regarding 
PROMs following a hospital admission episode for CAP in order to inform future research in this 
area. 
 
METHODS 
This systematic review was conducted and reported in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.11 The review protocol was 
prospectively registered in the PROSPERO database (CRD42017059799).12 
Search Strategy 
Comprehensive searches of biomedical electronic databases were conducted: Cochrane Central 
Register of Controlled Trials (CENTRAL 2017, Issue 3), MEDLINE (1946 to March week 3, 2017), 
EMBASE (1980 to March 2017), CINAHL (1981 to March 2017), AMED (1985 to March 2017), Web of 
Science (1985 to March 2017). The search strategy included subject headings and key words related 
to community-acquired pneumonia, symptom recovery, functional activity, healthcare utilisation 
and treatment outcome. The searches were not subject to any language restrictions.  Details of the 
search strategy for each database are found in Online Supplement - Appendix 1. An additional grey 
literature search was conducted using Google Scholar to identify unpublished data of potential 
significance to the review.  Reference lists of included studies were reviewed to identify potentially 
PROMs in CAP recovery; a systematic review. 
Version 1.0 (10.12.18) 
Page 4 of 30 
 
relevant articles. The full texts of identified articles were reviewed and assessed against eligibility 
criteria. Conference proceedings of the last 3 years for the American Thoracic Society Conference, 
British Thoracic Society Winter Meeting and European Respiratory Society Congress were reviewed 
to identify potentially eligible articles.  
Study selection 
Randomised controlled trials (RCTs), quasi-experimental, and non-randomised studies in adults 
attending secondary care facilities with a presenting diagnosis of CAP and assessing at least one of 
the pre-defined patient-reported markers of recovery were included. A diagnosis of CAP was defined 
as: symptoms and signs consistent with an acute lower respiratory tract infection associated with 
radiological confirmation of pneumonia on chest x-ray. Attendance at a secondary care facility was 
defined as any patient receiving their initial review and all or part of their treatment for CAP at an 
acute hospital facility, including Emergency department visits, with or without subsequent 
admission.  
Two study authors conducted sequential review of identified studies independently, proceeding 
from title to abstract to full-texts, with exclusions at each stage if studies did not fulfil eligibility 
criteria. Disagreement was resolved by discussion and consensus, involving a third review author as 
necessary. 
Outcome measures 
Primary outcomes of interest measured within 6 weeks following hospital discharge were a) patient 
reported symptoms, b) return to work and/or usual activities of daily living, and c) healthcare 
utilisation. Secondary outcomes of interest measured within 6 weeks following discharge were a) 
proportion with physician determined clinical cure in studies reporting symptomatic and functional 
recovery, and b) change in quality of life scores. (Outcomes occurring within six weeks of discharge was 
chosen as the time-point for assessment because we anticipated most studies would report outcomes at that 
time-point, and it coincides with the time-point at which other outcomes are commonly measured in studies 
of CAP.)  
Data extraction 
All data were independently extracted by two authors (HP, TM) using a pre-designed form that was 
initially piloted on five studies; any disparities were resolved by discussion and consensus, including 
a third reviewer as required. Where data were represented graphically within studies, Digitizelt© 
software (Version 2.3.3, www.digitizeit.de) was used to derive estimated values. Information on 
study population, outcome, and study design were collected. 
PROMs in CAP recovery; a systematic review. 
Version 1.0 (10.12.18) 
Page 5 of 30 
 
Assessment of risk of bias 
A specific quality assessment tool was created combining relevant aspects from the Newcastle-
Ottawa scale and the Down’s and Black Quality Assessment Tool.13,14 Each study was assessed for 
details pertaining to study period and location, participant selection, and outcome measure with a 
final total score out of six (with 0 representing low quality and 6 representing the highest possible 
quality rating.) 
Data synthesis 
Extracted results were reviewed to assess if adequate similarity existed with respect to outcomes to 
conduct a random effects meta-analysis using Stata © version 15 (StataCorp. 2017.) The I2 statistic 
was used to assist with assessment of heterogeneity between studies.  
 
RESULTS 
The search strategy identified 3958 articles of which 15 articles fulfilled eligibility criteria and were 
included in the systematic review. (See study flow diagram, Figure 1.)6,15-28 
Characteristics of included studies 
The characteristics of the 15 included studies are summarised in Table 1. Briefly, eligible studies 
included 2 RCTs, 8 prospective cohort studies, 1 retrospective cohort studies and 4 studies with 
cohort data for participants originally enrolled in RCTs. Six studies were restricted to patients with 
low and moderate severity CAP (Pneumonia Severity Index (PSI) classes I to III, PSI score <110, or 
CURB65 score 0-2)6,17-19,21,23 or age < 65 years.18,23 One study did not assess disease severity,28 and 
the remaining studies included patients of all disease severities with mean PSI across studies ranging 
from 76.2 (±32.8) to 106.2 (±23.9).15,16,20,22,24-27 Outcome measures of interest varied substantially 
between the included studies, with variable choice of outcome, tool for assessment, and timing of 
measurement. Individual study methodology is summarised in Table 2. 
Risk of bias in included studies 
Across all included studies the median quality score was 4.5 (IQR 4-5.) Three studies scored full 
marks at quality assessment.16,17,26 (see Online supplement - Table 1) All included studies defined 
their follow-up period, with all but a single study adequately defining study population and study 
period. The study populations were often restricted by selection criteria, such as age, severity of 
disease, level of dependency or residential status, see Table 1, but these selection criteria were 
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deemed appropriate when study design and outcomes of interest were considered. Included studies 
rarely reported loss to follow-up. 
Patient reported symptoms  
Six studies included data for patient-reported prevalence of symptoms within 6 weeks of 
discharge.15,18,20,22,23,27   
Four studies reported prevalence of symptoms for participants unselected for age or disease 
severity.15,20,22,27   At 28–42 days post-discharge, the commonest symptom reported was fatigue 
(range: 45% to 72.6% of patients), followed by cough (range: 35.3% to 69.7%) and dyspnoea (range: 
34.2% to 67.1%)(Figure 2).22 20,27 One study of patients attending for healthcare review within 30-
days of discharge observed that respiratory symptoms were reported in 75.2% of those attending 
primary care and 47.5% of those attending emergency departments.15   Restricting the population to 
working adults, two studies reported symptom prevalence at 4 weeks following discharge and found 
1 or more symptom was reported by 35.0% and 58.2% of participants, cough by 19.9% and 31.9%, 
dyspnoea by 16.8% and 27.5%, and fatigue by 12.1% and 25.7%.18,23 Chest pain (16.5%) and sputum 
production (11%) were reported by participants respectively in one of these studies.18 
Finally, in an email survey investigating average time for resolution of symptoms following CAP in 
adults aged ≥50 years (n=500), median time for resolution of cough was 7 days (IQR 2-14), dyspnoea 
14 days (IQR 7-43), chest pain 7 days (IQR 2-14), sputum production 7 days (IQR 7-14), fever 2 days 
(IQR 1-2), and fatigue 20 days (IQR 7-24).28  
 
Quantitative synthesis 
Random effects meta-analysis was performed on amenable data from 4 studies (n=1715) reporting 
outcomes at 4 weeks. 18,20,23,27 High levels of heterogeneity were evident. Summary estimates of the 
proportion of patients reporting 1 or more symptoms was 70% (95% CI 53% to 86%, I2=98.6%); 
cough 42% (95% CI 24% to 60%, I2=97.1%), dyspnoea 39% (95% CI 21% to 58%, I2=97.5%), and 
fatigue 42% (95% CI 10 % to 74%, I2=99.2%) (Figure 3 a - d.)   
 
CAP specific symptom scores 
Four studies included data derived from pneumonia symptom scores.6,19,26,27 Two studies (n=91 and 
n=95) used the CAP score (higher score signifying fewer symptoms); The median CAP scores  
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reported by El Moussaoui et al at days 3, 7, 10, 14 and 28 following admission were 56 (IQR 38-69), 
60 (IQR 37-75), 65 (IQR 37-86), 77 (IQR 61-88) and 75 (IQR 58-93), and Bruns et al reported that 
normalisation of CAP score, relative to retrospectively assessed baseline scores 6 weeks prior to 
admission, occurred in 32% of patients at 10 days following hospital admission, and 41.8% of 
patients at 28 days.6 
Two studies (n=169 and n=312) used the CAP-symptom score (lower score signifying fewer 
symptoms); Wootton et al observed the average CAP-symptom score at day 2 from admission was 
23.8 and at day 28 was 13.6, 27 Uranga et al, in an interventional trial of short course antibiotics, 
reported that average CAP-symptom score in the control group on Day 5 from admission was 24.7 
(±11.4) and on Day 10 was 18.6 (±9.0) with corresponding values in the intervention group of 27.2 
(±12.5) and 17.9 (±7.6).26  
Return to functional activity  
Five studies included data for time to return to normal activities16,18,20,21,26. Daniel et al found that 
51.1% of adults aged below 65 years had not resumed baseline ADLs at 4 weeks.18 In contrast, Fine 
et al found that 18.0% of ‘workers’ had not resumed baseline ADLs at 4 weeks compared to 42.8% of 
‘non-workers’.20    
The median time for return to normal activity reported by Uranga et al was 18 days (IQR 9-25) in the 
control group and 15 days (IQR 10-21) in the intervention group.26 Fine et al found the median time 
for return to ADLs in workers was 15 days and in non-workers was 24 days20  whereas Labarere et al 
found little difference in the median time for return to ADLs between workers (22 days (IQR 11-29)) 
and non-workers (20 days (IQR 9-29)).21    
Of two studies with relevant data, 34.3%18 and 31.9%20 of participants had not returned to work at 4 
weeks. Median time for return to work following discharge was 14 days.21,28   Adamuz et al reported 
that the median time taken off work by participants in the control group was 26 days (IQR 12.5-37) 
compared to 30 days (IQR 15-66.5) in the intervention group.16 
Healthcare utilisation  
In addition to PROMs, three studies reported rates of Primary Care consultation and/or Emergency 
Department (ED) attendance within 4 to 6 weeks following hospital discharge.15,16,18 Daniel et al 
found that 59.2%  had consulted primary care and 12.0% had attended EDs within 4 weeks.18 This 
compares with 18.0% and 20.3% attending primary care, and 18.4% and 21.4% attending EDs in the 
two studies from Adamuz et al.15,16 Of those re-consulting a GP, on-going or new respiratory 
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symptoms were reported by 68.8%  to 75.2% of patients. Pneumonia-related symptoms or signs was 
the reported reason for ED attendance in 47.5% to 84.6% of patients.16,18  
Other outcomes 
In relation to quality of life measures, a single Spanish study commented that “SF-36 score at 30 days 
following hospital discharge remained abnormal when compared to the reference scores for the 
Spanish population,” but no data were reported.17  Using the EQ-5D index, Nickler et al noted that 
29% of participants exhibited a decline in ADLs at 30 days and that the decline was associated with 
levels of pro-adrenomedullin and pro-atrial natriuretic peptide.24  
Physician assessed clinical cure was noted by Bruns et al in 88.9% of participants 28-days after 
discharge though only 41.7% of patients reported normalisation of symptoms and function (based 
on the CAP score) at the same time point.6 No data were provided on any correlation between 
clinical cure and CAP score. 
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DISCUSSION 
This systematic review confirms that a high proportion of patients report substantial symptomatic 
and functional impairments during the first 6 weeks of recovery following hospitalisation with CAP. 
These are accompanied by adverse impacts on the performance of ‘normal activities’, such as return 
to work, and healthcare utilisation. Fatigue, cough, and dyspnoea are the commonest symptoms 
reported. The prevalence of symptoms over the first 6 weeks of recovery vary across studies in 
accordance with severity of CAP and age of study cohorts. 
The majority of studies assessed the prevalence of symptoms and functional impairment at specific 
times (most commonly 4 weeks post-discharge) without reference to baseline prevalence. Given the 
high proportion of patients with chronic cardiac and respiratory conditions within study cohorts, this 
approach likely overestimates the contribution of acute pneumonia to the prevalence of patients’ 
symptoms during recovery.  That said, studies that measured PROMs at multiple time points during 
recovery all reported a declining trend in the prevalence of symptoms over time, up to 42 days post-
discharge.6,19,22,27 These findings suggest that many patients continue to have symptoms related to 
the acute pneumonia episode even at 6 weeks post-discharge.  
Fatigue is the commonest symptom to be reported during recovery. The importance of fatigue as a 
contribution towards reduced functional recovery in CAP has not been widely examined. In a 
qualitative study of patients with low-severity CAP, both extreme tiredness and need for sleep were 
reported as prominent symptoms during recovery.29  Quantitatively, the CAP-symptom score 
captures the degree of fatigue on a scale of 0-5.30  However, these assessments do not adequately 
reflect the complexity of fatigue as a symptom, nor its impact on functional recovery. In other 
conditions where fatigue is a prominent symptom, validated disease-specific, multi-dimensional 
tools have been developed to better quantify and assess fatigue.31,32 
Return to functional activity, measured as return to ‘normal activities’ or ADLs, was consistently 
reported as taking a median of 15 to 25 days in included studies. This measure is set alongside other 
included studies that consistently reported a large proportion of patients failing to resume normal 
activities within 4 weeks post-discharge.  One study, not included in this review, found that at 6 
weeks post-discharge, 12% of elderly persons had required a change of residence indicating a 
greater level of dependency.33 Overall, these studies suggest that the full burden of adverse health 
outcomes following an episode of CAP is likely to be higher than reflected in measures of symptom 
resolution alone.34 Experience from patients recovering from exacerbations of COPD where impaired 
lung function, exercise capacity, and quality of life persists despite apparent symptomatic resolution 
provides further support for this view.35-37   
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We identified only two relatively small studies that attempted to describe the correlation between 
PROMs and healthcare re-consultation.15,18 These studies suggest that persistence of pneumonia 
related symptoms is a major factor in GP re-consultations, while new or worsening comorbid 
illnesses increase in prominence in relation to ED re-attendances. An episode of pneumonia may be 
a marker for frailty or increased susceptibility to illness from non-pneumonia related factors.38 A 
better understanding of the association between PROMs, long-term complications and healthcare 
re-consultations is necessary if appropriate interventions are to be developed.  
 
Strengths and limitations 
As far as we know, this is the first systematic review of studies assessing PROMs in recovery from 
CAP. This review was conducted in accordance with PRISMA guidelines. Eligibility criteria were 
designed to focus the review on studies of patients with CAP and not on cohorts with hospital-
acquired pneumonia or aspiration pneumonia.  
We found only a small number of high quality research studies in this field compared to the large 
burden of disease. Existing studies are disparate in their study populations (age, co-morbid illness, 
and disease severity) and outcome measures (Table 2). Importantly, there is a lack of consistency 
across studies in the choice and application of measurement tools to assess PROMs. The CAP-
symptom score is the only available PROM psychometrically validated using a recognised approach, 
albeit only in an out-patient setting. These variations in outcome measures precluded many studies 
from the planned meta-analysis; the resulting meta-analysis retained high study heterogeneity. Most 
notably, the meta-analysis illustrates how, at a given time-point, the severity of CAP and / or age of 
the study cohort greatly affects estimates of symptom prevalence. 
Implications 
There is an important need for researchers to develop and agree on appropriate tools and 
methodology in the assessment of PROMs during recovery from CAP. Barlow et al previously defined 
core outcomes sets for CAP research, including recommending the CAP-symptom score for use in 
studies of recovery. 9 Ideally, the CAP-symptom score should be externally validated for hospitalised 
patients and a multi-dimensional CAP-specific tool for assessing fatigue developed 
In the meantime, considering the available evidence, we suggest the CAP-symptom score remains 
the most appropriate tool  for the measurement of symptoms, . As the prevalence of symptoms 
remains high for 2 – 4 weeks post-discharge, and healthcare re-consultation is concentrated to 
within the same time period, we suggest that PROMs should be assessed, at a minimum, twice post-
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discharge, at around 2 weeks and again at 4 or 6 weeks. To enable analysis of the degree of recovery 
at these time-points, an assessment at the time of hospital discharge is necessary, together with an 
assessment of ‘pre-pneumonia baseline’; accepting that the latter is inevitably subject to recall bias. 
In addition to symptom reporting, we recommend measuring functional recovery, both in terms of 
quality of life (EQ-5D) and return to normal activities. Ideally, the time needed to return to ‘baseline’ 
health status within different domains should be measured. These interim suggestions should be 
refined as new, stronger evidence emerges and our understanding of recovery from CAP increases.  
 
Conclusion 
Morbidity from CAP continues for a sizeable proportion of patients up to at least 6 weeks post-
discharge from hospital. There is a large relative lack of high-quality research in this field.  
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Figure 1. Study flow diagram  
 Records identified 
through database 
searching (n = 3952) 
Additional records 
identified through 
other sources (n = 6) 
Records after duplicates 
removed (n = 2753) 
Titles / Abstracts screened 
(n = 2753) 
Full-text articles assessed 
for eligibility (n = 103) 
Records excluded  
(n = 2650) 
Studies included in 
qualitative synthesis  
(n = 15) 
87 full-text articles excluded: 
No relevant outcome data (n = 74) 
Review article / letter to editor (n = 9) 
Overlapping population / dataset (n = 3) 
Mixed  primary and secondary care cohort 
(n = 2) 
Unable to access (n = 1) 
Studies included in 
quantitative synthesis  
(n = 4) 
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Figure 2 – Prevalence of symptoms in recovery following community-acquired pneumonia 
  
 
 
2 (a) Prevalence of 1 or more symptom in CAP recovery 2 (b) Prevalence of cough in CAP recovery 
 
2 (c) Prevalence of dyspnoea in CAP recovery 2 (d) Prevalence of fatigue in CAP recovery 
 
2 (e) Prevalence of chest pain in CAP recovery 2 (f) Prevalence of sputum production in CAP recovery 
 
* Studies in bold and underlined are from studies of patient cohorts restricted to either low-moderate severity CAP (PSI Class III or 
less, CURB65 0-2) or age < 65 years, by design. Marrie et al measured symptom prevalence twice (14days and 42 days), all other 
studies measured symptom prevalence once. 
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Figure 3 (a) to (d); Random effects meta-analysis of prevalence of symptoms at 4 weeks following discharge from hospital with community-acquired 
pneumonia. 
 = Studies that selected patients with low-moderate severity CAP or age <65 years
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Table 1. Summary of Included Studies 
First 
Author 
Country Study Period Study Type Study Population Outcome 
Studies with participants selected for low-moderate severity CAP or Age <65 years (n=6 studies, n=1217 individual participants) 
Bruns 
20106 
Netherlands 
November 2000 
- July 2003 
Multicentre 
prospective 
cohort 
119 adults with CAP 
 
CAP Aetiology:  
 Streptococcus pneumoniae 27.7% 
 
Selection criteria; 
 Age – unselected (mean age 56.6 (±17.8) 
 Severity – low severity, PSI<110 (mean PSI 65.5 (±22.1)) 
 Co-morbid disease – unselected 
 Immune status – unselected 
Normalisation CAP score at day 10 – 32.0% 
Physician rated clinical cure at day 28 - 88.9% 
Carratala 
200517 
Spain 
October 2000 - 
October 2002 
Cohort from 
Multicentre RCT 
224 adults with CAP – 101 patients in hospitalised cohort 
 
CAP Aetiology:  
• Streptococcus pneumoniae - 14.0% 
• Legionella pneumophila - 4.4% 
• Haemophilus influenzae - 2.6% 
• “Atypical” - 2.6% 
 
Selection criteria; 
 Age – unselected (mean age; outpatient group 67.5 (±11.8), 
inpatient group 64.9 (±13.4)) 
 Severity – low severity, PSI classes II & III (Mean PSI outpatient 
group 70 (±11.6), inpatient group 66.9 (±12.5)) 
 Co-morbid disease – excluded if pregnant, breast feeding, 
respiratory failure, concomitant unstable comorbid conditions 
necessitating hospitalisation, complicated pleural effusion, lung 
abscess, shock, metastatic infection, severe social problems, 
cognitive impairment, psychiatric disease. 
 Immune status – immunocompetent only (excluded HIV, 
splenectomy, immunosuppressive therapy, corticosteroid 
therapy, neutropenia, solid organ transplant) 
 Other – excluded if quinolone allergy or quinolone therapy in 
preceding 3 months 
 
SF-36 score; “At 30-day follow-up SF-36 scores remained 
abnormal, but had returned towards baseline for Spanish 
population” 
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First 
Author 
Country Study Period Study Type Study Population Outcome 
Daniel 
201818 
UK February 2015 - 
April 2016 
Multicentre 
prospective 
cohort 
108 adults with CAP 
Male – 48.2% 
 
CAP Aetiology:  
• Streptococcus pneumoniae – 16.7% 
  
Selection criteria; 
 Age – 18-65 years only (median age 50 (IQR 38.3-57.8)) 
 Severity – unselected (CURB65 0-1 = 88.9%, CURB65 2 = 9.3%, 
CURB65 ≥ 3 = 1.8%) 
 Co-morbid disease – unselected 
 Immune status – unselected 
 
Proportion of patient reporting prevalence of symptoms and 
functional impairment at 28days following discharge; 
Cough – 31.9% 
Dyspnoea – 27.5% 
Chest pain – 16.5% 
Sputum – 11.0% 
Fatigue – 12.1% 
1 or more symptom – 58.2% 
Not returned to ADLs – 51.1% 
No to returned to Work 34.3% 
Re-consultation within 28 days 
ED attendance – 12.0% 
Primary care – 59.2% 
El 
Moussao
ui 200619 
Netherlands 
November 2000 
- July 2003 
Cohort from 
Multicentre RCT 
91 adults with CAP 
Male 58.8% 
 
CAP Aetiology:  
• Streptococcus pneumoniae – 23.8% 
 
Selection criteria; 
 Age – unselected (median age 65 (IQR 48-72)) 
 Severity – low severity, PSI <110 (mean PSI 71 (±23) 
 Co-morbid disease – excluded if pregnant, severe underlying 
disease, preceding antibiotic treatment for >24 hours prior to 
admission, concurrent co-morbid disease likely to interfere with 
course of pneumonia, respiratory failure 
 Immune status – unselected 
Other – excluded if amoxicillin allergy 
Median CAP scores (IQR) 
Day 3 – 56 (38-69) 
Day 7 – 60 (37-75) 
Day 10 – 65 (37-86) 
Day 14 – 77 (61-88) 
Day 28 - 75 (58-93) 
Laberere 
200721 
USA / Canada 
January 2001 - 
December 2001 
Cohort from 
Multicentre RCT 
549 adults with CAP  
Male 44% 
 
CAP Aetiology: Not reported 
 
Selection criteria; 
 Age – unselected (median age 66 (IQR 48-77) 
 Severity – low severity, PSI classes I-III (PSI I – 16.0%, PSI II – 
41.0%, PSI III – 43.0% 
 Co-morbid disease – excluded if pulmonary tuberculosis, 
alcoholism &evidence of end-organ damage, social problems 
incompatible with recruitment, illicit drug use  30days 
Immune status – immunocompetent only (excluded if HIV, 
immunosuppression) 
Median time for return to ADLs Workers - 22 days (11-29) 
Non-workers - 20 days (9-29) 
Median time return to work - 14 days (8-29) 
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First 
Author 
Country Study Period Study Type Study Population Outcome 
Metlay 
199823 
USA April 1996 - 
February 1997 
Single centre 
prospective 
cohort 
126 adults with CAP  
Male – 54.8% 
 
CAP Aetiology: Not reported 
 
Selection criteria; 
 Age – 18 to 64 years 
 Severity – low severity, PSI classes I-III (mean PSI 55.2) 
 Co-morbid disease – excluded if pregnancy, severe 
neuromuscular disease 
 Immune status – immunocompetent only (excluded if chronic 
immunosuppression or HIV.)  
Other – nursing home residence, psychological or social problems 
compromising follow-up 
Proportion of patient reporting prevalence of symptoms at 
28days following discharge; 
Cough – 19.9% 
Dyspnoea – 16.8% 
Fatigue – 25.7% 
Fever – 3.5% 
1 or more symptom – 35.0% 
  
PROMs in CAP recovery; a systematic review. 
Version 1.0 (10.12.18) 
Page 22 of 30 
 
First 
Author 
Country Study Period Study Type Study Population Outcome 
Studies where participants were unselected for severity or age (n=9 studies, n=4427 individual participants); 
Adamuz 
201115 
Spain 
January 2007 - 
December 2009 
Single centre 
prospective 
cohort 
828 adults with CAP 
Male – 65.8% 
 
CAP Aetiology:  
• Streptococcus pneumoniae – 44.1% 
• Legionella pneumophila – 3.0% 
• Haemophilus influenzae – 4.4% 
• Anaerobes – 5.6% 
 
Selection criteria; 
 Age – unselected (median age 71 (IQR 55-79)) 
 Severity – unselected (PSI>90 IN 62.2%) 
 Co-morbid disease – unselected 
 Immune status – immunocompetent only (excluded HIV, 
splenectomy, immunosuppressive therapy, corticosteroid 
therapy equivalent to prednisolone >20mg daily, neutropenia, 
Ig deficiency, solid organ transplant) 
 Other – excluded if inpatient death 
Healthcare utilisation at 30 days 
ED – 21.4% 
Primary Care – 18.0% 
 
Symptoms reported in participants reconsulting within 30days 
Primary care (n=149) 
Respiratory symptoms – 75.2% 
General symptoms – 22.8% 
ED (n=177) 
Worsening pneumonia symptoms – 47.5% 
Adamuz 
201516 
Spain 
January 2011 - 
October 2014 
Multicentre RCT 
207 adults with CAP 
Male – 59.9% 
 
CAP Aetiology:  
• Streptococcus pneumoniae – 24.6% 
• Haemophilus influenzae – 5.4% 
• Influenzae A – 3.4% 
 
Selection criteria; 
 Age – unselected (21-49 = 20.2%, 50-69 = 30.5%, >70 = 49.3%) 
 Severity – unselected (CURB65 0-1 = 49.3%, CURB65 2 = 34.3%, 
CURB65 ≥ 3 = 16.4%) 
 Co-morbid disease – Excluded cognitive impairment 
 Immune status – immunocompetent only (excluded HIV, 
splenectomy, immunosuppressive therapy, corticosteroid 
therapy equivalent to prednisolone >20mg daily, neutropenia, 
Ig deficiency, solid organ transplant) 
 Other – excluded if nursing home resident or long-term care 
facility, language barrier 
Healthcare utilisation at 30daysPrimary care – 20.3% 
ED – 18.4% 
 
Median time off work; 
Intervention group – 30 days (IQR 15-66.5) 
Usual care group – 26 days  
(IQR 12.5-37) 
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First 
Author 
Country Study Period Study Type Study Population Outcome 
Fine 
199920 
USA / Canada 
October 1991 - 
March 1994 
Multicentre 
prospective 
cohort 
1343 adults with CAP 
Male 52.4% 
 
CAP Aetiology:  
• Streptococcus pneumoniae – 9.1% 
• Haemophilus influenzae 4.8% 
• “Atypical” – 2.1% 
•  Enterobacter sp. – 2.8% 
• Pseudomonas aeruginosa – 0.9% 
 
Selection criteria; 
 Age > 65years 58.7% 
 Severity – unselected (PSI I – 13.8%, PSI II – 17.4%, PSI III – 
18.9%, PSI IV – 33.2%, PSI V – 16.7%) 
 Co-morbid disease - unselected 
 Immune status – excluded if HIV 
Proportion of patient reporting prevalence of symptoms and 
functional impairment at 30days following discharge; 
Cough – 47.1% 
Dyspnoea – 46.5% 
Sputum – 42.3% 
Fatigue – 72.6% 
1 or more symptom – 68.5% 
Not returned to ADLs; 
Workers – 18%  
(median 15days) 
Non-workers – 42.8%  
(median 24 days) 
 
Not returned to Work 31.9% 
Marrie 
200022 
Canada 
January 1998 - 
July 1998 
Multicentre 
prospective 
cohort 
535 adults with CAP 
Male – 52.3% 
 
CAP Aetiology: Not reported 
 
Selection criteria; 
 Age – unselected (mean age 61.6 (±19.1) 
 Severity – unselected (mean PSI 76.2 (±32.8) 
 Co-morbid disease - unselected 
 Immune status – unselected 
Proportion of patient reporting prevalence of symptoms and 
functional impairment at 14days and 42days following 
discharge; 
Cough – 55.8%, 35.3% 
Dyspnoea – 48.6%, 34.2% 
Chest pain – 17.3%, 11.6% 
Sputum – 35.9%, 26.4% 
Fatigue – 66.7%, 45.0% 
Fever – 8.4%, 4.7% 
1 or more symptom – 85.6%, 64.3% 
Nickler 
201624 
Switzerland 
October 2006 - 
March 2008 
Cohort from 
Multicentre RCT 
753 adults with CAP 
Male 58.8% 
 
CAP Aetiology: Not reported 
 
Selection criteria; 
 Age – unselected (median age 72 (IQR 52-82) 
 Severity – unselected (PSI I – 10.0%, PSI II – 19.7%,  
 Co-morbid disease – excluded if terminal illness 
 Immune status – immunocompetent only (excluded if long-
term immunosuppression) 
 Other – excluded if language impairment precluding written 
consent, intravenous drug abuse. 
EQ-5D index – decline in ADLs in 29% at day 30 
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First 
Author 
Country Study Period Study Type Study Population Outcome 
Sharma 
200625 
USA 
March 1995 - 
March 1998 
Single centre 
prospective 
cohort 
79 adults with CAP 
Male – 35% 
 
CAP Aetiology: Not reported 
 
Severity criteria; 
 Age – unselected (mean age 79.9 (±6.1) 
 Severity – unselected (mean PSI 106.2 (±23.9) 
 Co-morbid disease – excluded if terminal illness 
 Immune status – unselected 
 Other – excluded if coma, intensive care admission, unable to 
participate in interview 
Proportion with decline in ADL score of greater than 1 point - 
22/79 (28%) at day 30 
Uranga 
201626 
Spain 
January 2012 - 
August 2013 
Multicentre 
Randomised 
Control Trial 
312 adults with CAP 
Male 62.8% 
 
CAP Aetiology:  
• Streptococcus pneumoniae – 16.0% 
• Legionella pneumophila – 3.5% 
• Haemophilus influenzae – 0.3% 
 
Selection criteria; 
 Age – unselected (mean age 62.2 (±6.07) and 64.7 (±18.7)) 
 Severity – unselected (mean PSI 83.7 (±33.7) and 81.8 (±33.8)) 
 Co-morbid disease – unselected 
 Immune status – immunocompetent only (excluded if HIV, 
immunosuppression for solid organ transplantation, 
splenectomy, receiving ≥10mg/d of prednisone or the 
equivalent for >30 days, taking other immunosuppressive 
agents, or neutropenia) 
 Other – excluded if care home resident, antibiotics within 
preceding 30 days, intercostal chest drain, extra-pulmonary 
manifestations, death or ICU admission prior to randomisation 
Mean CAP symptom score at 5 days 24.7(±11.4) to 27.2(±12.5) 
Mean CAP symptom score at 10 days 18.6(±9.0) to 17.9(±7.6) 
Median time for return to normal activity 15days (IQR 10-21) to 
18days (IQR 9-25) 
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First 
Author 
Country Study Period Study Type Study Population Outcome 
Wootton 
201727 
UK February 2011 - 
March 2013 
Multicentre 
prospective 
cohort 
169 adults with CAP 
Male 52% 
 
CAP Aetiology: Not reported 
 
Selection criteria 
 Age – unselected (mean age 68 (range 16-98) 
 Severity – unselected (CURB65 0-1 = 46.7%, CURB65 2 = 29.6%, 
CURB65 ≥3 = 23.7%) 
 Co-morbid disease – excluded if bronchiectasis, cystic fibrosis, 
advanced malignancy 
 Immune status – unselected 
 Other – excluded if palliative treatment, invasive ventilation 
Average CAP symptom score - 23.8 at day 2 
Average CAP symptom score - 13.6 at day 28 
Proportion of patient reporting prevalence of symptoms at 
28days following discharge; 
Cough – 13.6% 
Dyspnoea – 67.1% 
Chest pain – 31.2% 
Fatigue – 57.0% 
1 or more symptom – 96.4% 
Wyrwich 
201528 
USA Unknown 
Multicentre 
retrospective 
cohort 
201 adults with CAP 
Male – 45% 
 
CAP Aetiology: Not reported 
 
Selection criteria; 
Age – ≥50 years 
Severity – unselected 
Co-morbid disease – unselected 
Immune status – unselected 
Other – respondent to email survey, excluded in nursing home resident 
 
Average time to symptom resolution, in days; 
Cough; mean 13.6 
median 7 (2-14) 
Dyspnoea; mean 25.1 
median 14 (7-43) 
Chest pain; mean 12.9 
Median 7 (2-14) 
Sputum; mean 14.8 
Median 7 (7-14) 
Fatigue; mean 25 
Median 20 (7-24) 
Fever; mean 2.7 
Median 2 (1-2) 
Median time for return to work – 14 days 
PROMs in CAP recovery; a systematic review. 
Version 1.0 (10.12.18) 
Page 26 of 30 
 
Table 2. Summary of methodology of included studies 
Abbreviations; I/P – inpatient, O/P – outpatient, CURB65 – confusion, urea, blood pressure, age>65 years, PSI – Pneumonia severity index, CAP – community-acquired pneumonia, SF-36 – 
short-form health survey, EQ-5D – EuroQoL health-related quality of life questionnaire, ADLs – activities of daily living, ED – emergency department.
Study Destination 
after initial 
review 
Severity Outcome Measure Timing of assessment of outcome 
measure (days) Assessment of Symptoms Health Status Assessment of function 
(return to) 
Clinical 
Cure 
Healthcare 
utilisation 
I/P O/P CURB65 PSI Prevalence 
Symptoms 
CAP 
Score 
CAP-symptom 
score 
SF-36 EQ-5D ADLs Occupation Primary 
Care 
ED Average 
time to X  
≤14 28 30 42 
Studies with participants selected for low-moderate severity CAP or Age <65 years (n=6 studies, n=1217 individual participants) 
Bruns  
20106 
X   X  X      X    X X   
Carratala  
200517 
X X  X    X          X  
Daniel  
201818 
X  X  X     X X  X X   X   
El Moussaoui 
200619 
X   X  X          X X   
Laberere  
200721 
X X  X      X X    x     
Metlay  
199823 
 X  X X            X   
Studies where participants were unselected for severity or age (n=9 studies, n=4427 individual participants); 
Adamuz  
201115 
X   X X        X X    X  
Adamuz  
201516 
X  X        X  X X X   X  
Fine  
199920 
X X  X X     X X       X  
Marrie  
200022 
X X  X X           X   X 
Nickler  
201624 
X   X     X         X  
Sharma  
200625 
X   X      X        X  
Uranga  
201626 
X   X   X   X     X X    
Wootton  
201727 
X  X  X  X        X  X   
Wyrwich 
201528 
X X   X      X    X     
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Appendix 1 - Details of search strategies 
MEDLINE (Ovid) 
1. exp Pneumonia/ 
2. exp Community-Acquired Infections/ 
3. “community-acquired pneumonia.tw. 
4. exp “Outcome Assessment (Health Care)”/ 
5. exp “Recovery of Function”/ 
6. exp “Activities of Daily Living”/ 
7. exp Symptom Assessment 
8. exp Treatment Outcome/ 
9. exp Patient Readmission/ 
10. symptom recovery.tw. 
11. symptomatic recovery.tw. 
12. functional recovery.tw. 
13. 1 and 2 
14. 3 or 13 
15. OR/ 4-12 
16. 14 and 15 
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EMBASE (OVID) 
1. exp pneumonia/ 
2. exp community acquired infection/ 
3. community acquired pneumonia*.tw. 
4. community-acquired pneumonia*.tw. 
5. 1 and 2 
6. OR/ 3-5 
7. exp outcome assessment/ 
8. recovery of function*.mp. or exp convalescence/ 
9. exp daily life activity/ 
10. exp symptom assessment/ 
11. exp treatment outcome/ 
12. exp hospital readmission/ 
13. symptom recovery*.tw. 
14. symptomatic recovery*.tw. 
15. OR/ 7-14 
16. 6 and 15 
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AMED (OVID) 
1. exp Pneumonia/ 
2. community-acquired infection*.mp. 
3. community-acquired pneumonia*.mp. 
4. community acquired pneumonia*.mp. 
5. OR/ 1-4 
6. exp "recovery of function"/ 
7. exp "Activities of daily living"/ 
8. exp Symptoms/ 
9. exp Treatment outcome/ 
10. exp Rehabilitation/ 
11. patient readmission*.mp. 
12. functional recovery*.mp. 
13. OR/ 6-12 
14. 5 and 13 
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Appendix 2; Online supplementary material; Table 1; Risk of bias in included studies 
 
First Author Primary Outcome 
Selection 
Domain (max 3) 
Outcome 
Domain (max 3) 
Comments 
Adamuz 2011 Additional healthcare utilisation within 30days of discharge 3 2 Outcome measure not clearly defined or justified 
Adamuz 2015 Additional healthcare utilisation within 30days of discharge 3 3  
Bruns 2010 Rate of radiographic resolution 2 2 20.1% loss to follow-up 
Carratala 2005 Successful outcome' - composite of 7 predefined criteria 3 3 Low severity CAP (PSI classes II and III only) 
Daniel 2018 Healthcare re-consultation within 4 weeks of discharge 2 3 Working age adults, low severity CAP 
El Moussaoui 2006 Pneumonia related symptoms during follow-up 2 2 Low severity CAP 
Fine 1999 
Not defined - process of care and outcome of outpatients and hospitalised 
patients with CAP 
2 2  
Labarere 2007 30 day mortality rate 2 3 Low severity CAP 
Marrie 2000 Proportion of patients with symptom resolution at 6 weeks 2 2 No details regarding loss to follow-up 
Metlay 1998 Proportion of patients with symptom resolution at 4 weeks 2 2  
Nickler 2016 Decline in QoL from hospital admission (baseline) to day 30 and after 6 years. 
2 2 
Not representative sample excluded elderly, 
dementia, significant co-morbid disease 
Sharma 2006 
Decline in ADL score by at least 1 point, comparing baseline prehospitalization 
ADL to 1 and 6 months post discharge. 
2 2 
Not representative sample, from cohort study of 
delirium in elderly, no details on loss to follow-up 
Uranaga 2016 Clinical success rate at day 10 and day 30 since admission 3 3  
Wootoon 2017 Time for symptomatic recovery to baseline 
2 2 
Excluded patients with cognitive impairment, no 
loss to follow-up information 
Wyrwich 2015 Time for symptom resolution 0 2  
